Abstract:Current therapeutic options for non-small cell lung cancer (NSCLC) patients are chemotherapy and targeted therapy directed mainly against epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements. Targeted therapy relies on the availability of tumor biopsies for molecular profiling at diagnosis and to longitudinally monitor treatment response and resistance development. Unfortunately, tumor biopsy might be invasive, recover poor material of suboptimal quality, and cause sample bias due to tumor heterogeneity. Many studies have illustrated the potential of liquid biopsy as minimal invasive approach to respond to the urgent need for real time monitoring, stratification, and personalized optimized treatment in NSCLC patients. In principle, the liquid biopsy could provide the genetic landscape of primary and metastatic cancerous lesions, detecting "druggable" genomic alterations or associated with treatment resistance. Moreover, it would guarantee the prognostic/predictive biomarkers evaluation in patients for whom biopsies are inaccessible or difficult to repeat. At this regard, the prognostic value of circulating tumor cells (CTCs) in NSCLC patients has been largely investigated, but still their clinical utility as tumor biomarker is hampered by the lack of a consensus on the criteria necessary and sufficient to define them and on the standard operating procedures (SOPs) for their assessment. This review will summarize current developments on liquid biopsy in NSCLC, addressing the technology issues that contribute to the poor ability to track CTCs in the blood of NSCLC patients, thus limiting their extensive use in the clinical practice, and analyzing the solutions adopted to overcome such limits, on the road towards the clinical validation.

Liquid biopsy in lymphomas: a potential tool for refining diagnosis and disease monitoring

Liquid biopsy in hematological malignancies: current and future applications

Liquid Biopsy: A New, Non-Invasive Early Diagnostic and Prognostic Tool in Oncology

Controversies in the Interpretation of Liquid Biopsy Data in Lymphoma

Liquid Biopsies, Novel Approaches and Future Directions

Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer

Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments

Recent advances in the use of liquid biopsy for the diagnosis and treatment of lung cancer

Liquid biopsy: A promising tool for driving strategies and predicting failures in patients with classic Hodgkin lymphoma

Liquid Biopsies: Applications for Cancer Diagnosis and Monitoring

Liquid Biopsy in the Management of Breast Cancer Patients: Where Are We Now and Where Are We Going

Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung Cancer: A European Perspective

Critical issues in the clinical application of liquid biopsy in non-small cell lung cancer

Liquid biopsy: Exosomal microRNAs as novel diagnostic and prognostic biomarkers in cancer

The Emerging Role of Liquid Biopsies in Lymphoproliferative Disorders

The Liquid Biopsy Consortium: Challenges and Opportunities for Early Cancer Detection and Monitoring

Liquid biopsy in lymphoma: Is it primed for clinical translation?

Liquid Biopsy: A New Translational Diagnostic and Monitoring Tool for Musculoskeletal Tumors

Liquid biopsy in cholangiocarcinoma: Current status and future perspectives

Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?

Hodgkin lymphoma and liquid biopsy: a story to be told